Industry Outlook 1999/ Diagnostics
Putting a positive spin on the diagnostic industry's prospects for growth these days isn't easy. Two industry experts--Henry Weinert of Boston Biomedical Consultants and Bob Easton of The Wilkerson Group--discuss the structural changes that are putting so much pressure on the industry, and the few areas which they think are opportunities for growth, namely point-of-care diagnostics and histopathology.
You may also be interested in...
The diagnostics industry grew an estimated 7% from 2000 to 2001, to more than $20 million, with 8% projected for this year, according to Boston Biomedical Consultants. While in some industries, that figure might be considered lackluster, in diagnostics it is far better than the norm, especially considering that the growth was solid and broad, benefiting most top companies in many product categories.
As signaled when Pfizer acquired Biohaven’s Nurtec and CGRP assets, Biohaven will continue under a modified name, with a focus on epilepsy, obsessive compulsive disorder and spinal muscular atrophy.
A legal expert details how Piramal Healthcare could turn the tables and secure damages in the litigation pertaining to its generic version of Amgen's Sensipar, a case which saw multiple at-risk launches.